A method for determining a safety range for non-cancer risks is proposed, similar in concept to 20 the range used for cancer in the management of waste sites. This safety range brings 21 
Introduction 41
Risk managers responsible for making choices about acceptable oral and inhalation chemical 42 exposures at hazardous waste sites 1 have typically focused first on concerns about cancer. As 43 risk managers became increasingly familiar with how to effectively manage these cancer risks, it 44 became routine to make screening and closure decisions using the widely accepted 100-fold 45 upper-bound, excess, lifetime, cancer risk range of 10 -4 to 10 -6 (U.S. Environmental Protection 46
Agency (EPA), 1991a). This range allowed managers the flexibility needed to address the risk at 47 waste sites that differed with respect to environmental setting, history, and current and future 48 uses, based on the needs of the community. 49
50
Risk managers have also always considered non-cancer health effects in this process, but such 51 effects often did not drive management decisions, or when they did, the evaluation lacked a 52 corresponding non-cancer risk range. For example, risk managers generally applied a Hazard 53 Quotient (HQ) of 1 as the criterion for a non-cancer effect, rather than applying a range of 54 acceptable HQ values. 2 The HQ concept is used by various agencies, each using its allowable 55 health protective level as the denominator in the equation (for examples of these levels please 56 1 Waste sites throughout the United States are often managed using risk assessment information and methods from the U.S. Environmental Protection Agency (EPA). Risk-based, medium-specific concentrations such as Regional Screening Levels (RSLs) (formerly known as risk-based concentrations (RBCs) or preliminary remediation goals (PRGs)) have been derived using these EPA methods (EPA, 1989 (EPA, , 1991b (EPA, , 2004 (EPA, , 2009 (EPA, , 2012a and have been widely used in the assessment and management of siterelated risks from environmental sources. 2 For ingestion exposures, the hazard quotient (HQ) is the ratio of an average daily dose to the Reference Dose (RfD). For inhalation exposures, the HQ is the ratio of the exposure concentration of a substance (EC) to its Reference Concentration (RfC). The HQ associated with acceptable exposures is generally one (1), with a precision of one significant figure (i.e., an implicit HQ range of 0.95 to 1.5). see: http://toxnet.nlm.nih.gov/newtoxnet/iter.htm). Although EPA (Barnes and Dourson, 1988; 57 EPA, 1994; 2002) and others such as Felter and Dourson (1998) have shown that the information 58 underlying the HQ, that is, the Reference Dose (RfD) or Reference Concentration (RfC) 59
[collectively referred to here as the RfD(C)], possesses "uncertainty spanning perhaps an order of 60 magnitude," risk managers have generally not implemented decisions based upon this stated 61 uncertainty. Consequently, non-cancer hazards have frequently been evaluated and regulated as 62 if a bright line existed when exposures were at, or very near, the RfD or RfC, i.e., where the 63 hazard quotient of one (1) or less was interpreted as without risk, and values greater than 1 were 64 associated with some unspecified, unacceptable risk. 65
It can be easily argued that the phrase in the definition of an RfD(C) "with uncertainty spanning 66 perhaps an order of magnitude" is precautionary. This is because the RfD(C) derivation process 67 contains several uncertainties, and the application of a factor for each of these uncertainties 68 provides a margin of safety based on the behavior of the "average" chemical (Dourson and Stara, 69
1983; Dourson et al., 1996) . Since most determinations of the RfD(C) have more than one source 70 of uncertainty, and consequently exhibit multiple successive precautionary adjustments (i.e., the 71 application of multiple uncertainty factors), this implicit margin of safety increases as the overall 72 uncertainty factor gets larger, as does the implicit protectiveness of the resulting RfD(C), as 73 demonstrated theoretically by Swartout et al. (1998) . Since their origin by Barnes and Dourson (1988) and EPA (1994), RfDs and RfCs have 75 increasingly been based upon more sophisticated data, algorithms and models (e.g., Renwick, 76 1991 Renwick, 76 , 1993 Renwick and Walker, 1993; Jarabek, 1995a Jarabek, , 1995b The uncertainty in each RfD(C) value includes its inherent precision and safety. Precision refers 159 to the repeatability of the overall process. What this means for a RfD(C) is how close a second 160 RfD(C), estimated for the same chemical given the same information, would be if developed by 161 a different expert or expert group. In such cases, the precision might be best characterized as 162 perhaps three-fold on either side of the RfD(C) (Felter and Dourson, 1998; EPA, 2002) , although 163 this could be less than or greater than a three-fold margin, as described above. 164
Within the uncertainty of each RfD(C), the concept of safety refers to the determination of its 165 degree of protectiveness. This degree of protectiveness is expected to vary, because a RfD(C) is 166 developed using one or more uncertainty factors, each of which is protective based on the 167 observed behavior of the "average" chemical (Dourson and Stara, 1983; Dourson et al., 1996) . 168
This protectiveness provides assurance that any RfD(C) is an underestimate of the expected 169 value of the actual safe dose, i.e., the No Observed Adverse Effect Level (NOAEL) for a 170 sensitive human subpopulation.
3 Furthermore, the use of multiple uncertainty factors results in 171 even more protective RfD(C) values as theoretically demonstrated by Swartout et al. (1998) . 172
Because of this, the portion of the uncertainty in an RfD(C) associated with safety is best 173 characterized as a range above the RfD(C), where the latter is considered as the floor to this 174 safety range, i.e., the RfD(C) is the lowest value within the range (Dourson and Stara, 1983; 175
Felter and Dourson, 1998). this precision is either 30% lower or 50% higher. 210
In contrast to precision, the safety in each of the three candidate RfC values for TCE is 211 associated with a unique range of values that is expected to lie above each candidate RfC, 212
because choices made at each step in the process of its derivation incorporate a margin of safety. 213
These choices include judgments of critical effects of differing severity, the use of an effect that 214 may not relate to humans, the use of a lower limit on the benchmark dose (BMD), and/or the use 215 of a 10-fold default uncertainty factor in lieu of data suggesting that a smaller uncertainty factor 216 may be more appropriate. The range of safety may not be the same among these candidate RfC 217 values because each was developed using a different critical effect, POD and aggregate 218 uncertainty factor. 219
For risk management decisions, the range of safety associated with each RfD or RfC is generally 220 more important than the respective range of precision. This is because risk managers are 221 interested in making decisions that are protective of public health and it is an understanding of 222 the range of safety in each RfD or RfC that is generally more informative. With this risk 223 management mindset, we determined a unique safety range associated with each candidate RfC 224 for TCE as follows. 225
For each candidate RfC, the safety range is defined by a floor value based upon the actual 226 candidate RfC point value, as described on IRIS. This choice of the individual candidate RfC as 227 the floor of the range for each non-cancer endpoint is reasonable from a practical point of view, 228 because managers are unlikely to take regulatory action at or below these values, due to the 229 protective nature implicit in the derivation of each candidate RfC, as described above. However, 230 using the RfD or RfC as the floor to a range in its value also has theoretical support where it is 231
shown that uncertainty factors are protective based on the behavior of the average chemical (see 232 Methods). These floor values for each endpoint-specific safety range are shown in Table 1 . 233
234
For each candidate RfC, the safety range is also defined by a ceiling value based upon the POD 235 for each candidate RfC, as described on IRIS. This ceiling value is then further adjusted 236 downward, if needed, to reflect the known toxicokinetic differences between the test organism 237
and the human population in order to determine the human equivalent concentration, and/or 238 known uncertainties in the overall database, such as the lack of NOAEL, a study of sufficient 239 duration, or the lack of a study investigating important endpoints. These reductions are based on 240 available data, or a default factor of three as per EPA (2002) . The intent of these reductions, if 241 needed, is to estimate the likely human equivalent NOAEL from a chronic experimental animal 242 study (or other study duration, if appropriate for the endpoint). The use of three-fold uncertainty factor represents the midpoint of the uncertainty factor of 10 251 for use of a LOAEL. Each of these ceiling values is reasonable from a practical point of view, 252 because risk managers are likely to take regulatory action at or above these values due to the fact 253 that specific toxic effects can sometimes be associated, or be anticipated, with them. These 254 ceiling values for each endpoint-specific safety range are also shown in Table 1 . candidate RfC. This is due to its small aggregate uncertainty factor of 10 (which argues for a 279 value closer to the candidate RfC), shallower hazard slope (which argues for a value farther from 280 the candidate RfC), low confidence 6 in the critical effect (which argues for a value farther from 281 the candidate RfC), and low confidence in the choice of a benchmark response of 1% (which 282 argues for a value farther from the candidate RfC). See also supplemental materials. 283
For the toxic nephropathy endpoint based on the NTP (1988) study, we judged the intermediate 284 value of the endpoint-specific uncertainty range to be 9 µg/m 3 , or three-fold above its respective 285 candidate RfC. This is due to its small aggregate uncertainty factor of 10 (which argues for a 286 value closer to the candidate RfC), steeper hazard slope (which argues for a value closer to the 287 candidate RfC), medium confidence in the critical effect (which argues for a value neither closer 288 to nor farther from the candidate RfC), and medium to low confidence in the choice of a 289 benchmark response of 5% (which argues for a value farther from the candidate RfC). See also 290 supplemental materials. 291 respective candidate RfC due to its larger uncertainty factor of 100 (which argues for a value 294 farther from the candidate RfC), medium confidence in the critical effect (which argues for a 295 value neither closer to nor farther from the candidate RfC), and medium to low confidence in its 296 choice of a lowest observed adverse effect level (LOAEL) as the POD (which argues for a value 297 farther from the candidate RfC). The effect shown by Keil et 
The safety range for each candidate RfC is shown in Table 1 . 301
302
Defining the Multi-endpoint Range of Safety 303
Since EPA developed three candidate RfCs for non-cancer effects, the endpoint-specific safety 304 range of each of the candidate RfCs may be considered individually, or collectively, in risk 305 management decisions. From the collective evaluation of the endpoint-specific safety ranges of 306 all three candidate RfCs, a "total safety range" of 2 µg/m 3 to 63 µg/m 3 may be inferred. However, 307 extraction of a "multi-endpoint safety range" from the broader total safety range may be more 308 useful for risk management decision-making. The multi-endpoint safety range may be defined 309 here as an estimate of "a daily exposure to the human population (including sensitive subgroups) 310 that is likely to be without an appreciable risk of deleterious effects during a lifetime." This is 311 based upon the definition of the RfD(C) (Barnes and Dourson, 1988; EPA, 1994 EPA, , 2002 , but 312 where the phrase "with uncertainty spanning perhaps an order of magnitude" is absent, because 313 the range is now specified for each RfD(C) value. 314
The POD for the RfD(C) is typically (although not always) based upon a NOAEL from a single 315 study for a single critical effect. The assessment of confidence levels in the study design, critical 316 effect and POD of a single study and critical effect enables the assignation of uncertainty factors 317 in a relatively straightforward manner. The use of the definition of the RfD(C) to also define the 318 multi-endpoint safety range is a recognition of the complexity associated with the prediction of a 319 "safe dose" or "safe concentration" associated with multiple effects, observed in multiple studies 320 and species, and multiple PODs, each variously based on a BMDL 01 , BMDL 05 or LOAEL value, 321 appropriately averaged over two different exposure periods, as relevant for developmental or 322 chronic effects. Therefore, the concept of a "safe dose" for the non-cancer effects of TCE has 323 been applied here to a range of values (i.e., the multi-endpoint safety range) which represents a 324 "safe concentration" for multiple endpoints and multiple studies, with various degrees of 325 confidence in study design, critical effect and POD, as illustrated by the shaded cells in Table 1 . 326
Specifically, the multi-endpoint safety range of the RfC for TCE was determined by careful 327 discernment of the confidence, precision and safety associated with each endpoint-specific floor, 328 intermediate and ceiling value. The floor of the multi-endpoint uncertainty range of the RfC for 329 TCE was determined by comparing the candidate RfC values from each of the three studies (i.e., 330 2 µg/m 3 for both the decreased thymus weight and fetal cardiac malformation endpoints, and 3 331 µg/m 3 for the toxic nephropathy endpoint). These three floor values are so closely clustered that, 332 based on the inherent precision, the values are toxicologically indistinguishable. The endpoint-333 specific floor value of 3 µg/m 3 based on toxic nephropathy represents the endpoint-specific floor 334 value of the highest overall confidence from among the three endpoint-specific floor values (see 335 decreased thymus weight is substantially higher. Therefore, the endpoint-specific ceiling value 357 for fetal cardiac malformations (20 µg/m 3 ) has been selected here as the ceiling value for the 358 multi-endpoint uncertainty range. Although the POD is of low confidence, the value is based on 359 the HEC 99 (calculated from the BMDL 01 ), and is a plausible yet conservative estimate of the 360 "safe concentration" for human exposures. 361
In summary, the confidence in each of the endpoint-specific safety ranges was subsequently 362 considered in the determination of the multi-endpoint safety range for risk management purposes 363 exposures that is primarily below the multi-endpoint safety range of 3 µg/m 3 to 20 µg/m 3 , then 381 the probability of inducing any non-cancer effects in the exposure population is lower and the 382 priority for any risk management action is reduced (see Figure 1a) . In this case, a risk manager 383 may decide to take no action, or to delay action pending further information. Such action would 384 be readily seen as the current practice at waste sites throughout the country. In contrast, when the exposure assessment defines a range in exposures that is primarily above 390 the multi-endpoint safety range of 3 µg/m 3 to 20 µg/m 3 , then the probability of inducing non-391 cancer effects in the exposure population is higher and the priority for risk management action is 392 increased (see Figure 1c) . In this case, a risk manager may decide to take action, or to ask for 393 specific information that would refine the estimates of health risk and/or exposure. Likewise, 394 such action would be readily seen as the current practice at waste sites throughout the country. 395
When the exposure assessment defines a range in exposures that is primarily in the multi-396 endpoint safety range of 3 µg/m 3 to 20 µg/m 3 , then risk managers can use the intermediate value 397 A relatively small proportion of exposures is higher than 9 µg/m 3 . Limited action may be warranted for risk management in this safety range, that is 9 µg/m 3 and other site considerations, to gauge whether a 398 management action is needed or if further information should be sought (see Figure 1b) . 399 400
Discussion 401
In this paper, a "safety range" is proposed for each RfD(C). This safety range provides further 402 clarification to the phrase "with uncertainty spanning perhaps an order of magnitude" in the 403 definition of the RfD(C). This safety range can also be used with exposure measurements at 404 waste sites to develop a "hazard range" 8 to facilitate risk management decisions for non-cancer 405 health effects. This hazard range is similar in concept to the upper bound, excess, lifetime, cancer 406 risk range of 10 -6 to 10 -4 . 407
The lower end of this safety range is the value of the RfD(C); the lower end for the 408 corresponding hazard range is a HQ value of 1. These lower bounds are not only consistent with 409 the definition and intent of any RfD(C) value, but also reflect typical risk management decisions 410 about HQs at waste sites. The upper end of either of these ranges can vary depending in part on 411 the basis of choice of and confidence in the critical effect, the relevant POD and any of its 412 necessary adjustments, the aggregate uncertainty factor, and, for the hazard range, the 413 uncertainty inherent in the estimates of exposure. For the safety ranges derived specifically for 414 the three TCE RfCs, the upper end varies from 10 to ~30 times above the RfD(C). 9 Some of these suggestions have been adopted here. 437
Additional discussion is warranted with respect to establishing the floor of our multi-endpoint 438 safety range for TCE. The mathematical precision of the cardiac or immune endpoint-specific 439 floor value of 2 µg/m 3 corresponds to a range of 1.5 µg/m 3 to 2.5 µg/m 3 ; the mathematical 440 precision of the nephropathy endpoint-specific floor value of 3 µg/m 3 corresponds to a range of 441 2.5 µg/m 3 to 3.5 µg/m 3 . Thus, the ranges associated with the implicit precision of the three 442 endpoint-specific floors coincide at a precision of one significant figure. Since the endpoint-443 specific value of 3 µg/m 3 based on toxic nephropathy has the highest overall confidence from 444 among the three endpoint-specific floor values (see Table 1 
474
It should be recognized that risk management decisions at different waste sites may differ, even 475 for the same set of chemicals with the same underlying hazard information, because other 476 10 Based on the available information, the human heart starts developing between days 13 and 15 after gestation or later and may be completely formed by 37-39 days into gestation or later, indicating the length of cardiac development in humans during fetal growth to be 24-26 days. Since EPA's RfC is based on all effects that occurred during the whole time of cardiac development in the rat by Johnson et al. (2003) , it is reasonable to use the whole time of cardiac development in humans, 24-26 days, as the averaging time for risk management decisions. This range falls within the previously stated range of 21 to 30 days (see supplemental materials), and for similar reasons. 
